Publications by authors named "A J Cuesta"

Host-pathogen interactions and the design of vaccines for aquaculture fish viruses are challenging and call for innovative approaches. This study explores the potential of adenoviral (Ad) vectors Ad5 and chimeric Ad5/40 as gene delivery tools for fish brain cells susceptible to neurotropic viruses. For this purpose, European sea bass () DLB-1 and gilthead seabream () SaB-1 brain cell lines were infected with Ad5 or Ad5/40 vectors expressing GFP, and we evaluated their capacity for infection by fluorescence microscopy and flow cytometry, as well as their antiviral innate immune response by the transcription of gene markers ( and ).

View Article and Find Full Text PDF

The aim of the study was to investigate the potential preventive use of short-chain fatty acids (SCFAs) to modulate inflammatory responses in gilthead seabream (Sparus aurata) skin. Initially, in vitro experiments were conducted to evaluate the effects of various concentrations of butyric acid, acetic acid and propionic acid, as well as their combination, on the cytotoxicity and cell viability of three different cell lines. The results determined the safe concentration of SCFAs, which was then used for an in vivo study.

View Article and Find Full Text PDF

Postbiotics are metabolic by-products from microorganisms that provide health benefits to the host. Their secretion can be influenced by various conditions affecting bacterial metabolism. This study presents a novel approach for producing potential postbiotics, specifically extracellular products (ECPs), from the probiotic strain Shewanella putrefaciens SpPdp11, grown under different culture conditions.

View Article and Find Full Text PDF

Aging is one of the main factors associated with cardiovascular diseases. Androgens exert beneficial effects on the cardiovascular system and testosterone (TES) replacement therapy improves cardiometabolic risk factors. However, TES is contraindicated in patients with prostate cancer due to its proliferative effects on prostatic tumor cells.

View Article and Find Full Text PDF
Article Synopsis
  • Avatrombopag is a newly approved treatment for immune thrombocytopenia (ITP), with limited real-world effectiveness and safety data available.
  • A study by the Spanish ITP Group involving 268 patients showed that 90.1% of those with low platelet counts improved significantly after starting the drug, with many achieving stable platelet levels.
  • The treatment allowed most patients to reduce or stop corticosteroid use, and only a small percentage experienced thrombocytosis or thromboembolic events, indicating its potential as an effective management option for ITP.
View Article and Find Full Text PDF